CompletedNCT00161031

Atomoxetine added to antipsychotic treatment for cognitive difficulties in schizophrenia

About this title

Medication studyAges 18–60United States

The study in practice

Understand this study

Listed age limits: 18 years to 60 years.

Listed locations: Baltimore and 1 more locationSee all locations and recruitment

Study clarity

Study start dateStarted: April 2004

Recruitment status: Completed
Enrollment listed in the registry: 30
Sponsor: University of Maryland, Baltimore
Sponsor type: University
Study type: Drug
Intervention type: Medication / drug
Study phase: Not clearly listed
Locations: United States
Age range: From 18 Years to 60 Years
Official registry ID: NCT00161031
Official title: Show the full official title
Atomoxetine as an Adjunct to Novel Antipsychotic Medication in the Treatment of Cognitive Deficits of Schizophrenia

Completed

Baltimore · Catonsville

FAQ

Who is behind this study?

The study sponsor is University of Maryland, Baltimore, a university.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine.

Who was this study for?

Listed age limits: 18 years to 60 years.